This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Beta Site: This is a new site which is still under development. We welcome your feedback, which will help improve it.

Feedback form

Transforming the treatment of stroke

 
Transforming the treatment of stroke

More than 100 years ago the Canadian doctor William Osler, a man often called the father of modern medicine, made the famous statement that: ‘it is the duty of the physician to explain to the patient or his friends that the condition is beyond relief, that medicine and electricity will do no good, and that there is no possible hope of cure’.

But in the 1990s and early 2000s, things were changing dramatically for stroke, a condition with no treatment and that often proved fatal. A meta-analysis of a number of small stroke trials conclusively showed that care on specialist stroke units reduces death and disability after stroke. And a randomised controlled trial conducted in the United States showed that alteplase, a clot-busting (thrombolytic) drug used in the treatment of heart attacks, was also effective at treating strokes, but only if given within three hours of stroke onset.

It was in these exciting times in the world of stroke that Professor Gary Ford spent his early years as a consultant, working as a clinical academic with interest in geriatric medicine and pharmacology in Newcastle upon Tyne.

An early adopter of game changing interventions

Acting on these momentous findings, Prof Ford set up the stroke unit and - as one of the first in the UK - the thrombolysis service in Newcastle. The pathway he developed has since been used as a template for thrombolysis in many stroke units in the UK. As the national lead of the international Safe Implementation of Thrombolysis in Stroke (SITS) programme, Prof Ford coordinated the UK arm of the SITS International Stroke Thrombolysis Registry, which provides data on the use of alteplase that have informed clinical practice worldwide. This registry and the associated training courses have allowed many more clinicians to provide thrombolysis treatment safely.  

To support paramedics and A&E staff in identifying patients with stroke, Prof Ford and his team developed the Face Arm Speech Test (FAST) and the Recognition of Stroke in the Emergency Room (ROSIER) tool. Both screening tools are now used nationally and internationally to identify strokes rapidly and allow faster treatment.

FAST was proving so simple and effective that the tool was subsequently promoted beyond medical and academic circles in a national public campaign. Most adults in the UK are now aware of the signs of stroke, and it is quite usual for patients to be brought to hospital as a result of a relative who has done the FAST test, recognised that the signs indicate a potential stroke, and called an ambulance.

A world leader in stroke research networks

In 2005, Prof Ford set up the National Institute for Health Research (NIHR) Stroke Research Network. This infrastructure, which initially comprised eight regional networks with research staff in almost every stroke service in the country, has led to a massive increase in the ability of hospitals to enroll patients into large multicentre studies in stroke. Thanks to this network,  UK patients and healthcare staff have been able to take part in practice-changing trials such as IST-3, CLOTS 1-3, ENOS, ENCHANTED, INTERACT-2, and SO2S.

The network made the UK a ‘go-to’ place for large multicentre academic and industry funded research studies. This model was so successful that it has been adopted by the National Institute for Health in the US (StrokeNet), and more recently also by Europe (ESO stroke net) and internationally (Global Alliance of Independent Networks focused on Stroke trials; GAINS). Prof Ford is now rightly seen as a world leader for development of stroke research networks.  

Prof Ford also introduced the concept of hyperacute stroke research centres with extended research nurse and clinician cover and facilities for advanced imaging and interventional treatments. Ten of these were funded by the NIHR in 2008 to facilitate state-of-the-art acute stroke trials such as the PISTE study, one of eight large multicentre trials that demonstrated that mechanical thrombectomy is safe and effective. The centres, which I now lead, greatly boosted recruitment to complex hyperacute stroke trials and put into place infrastructure that is now the foundation for the development of thrombectomy services in the UK. Demonstrating effectiveness of this procedure has changed clinical practice worldwide, with many more stroke patients recovering with no or minimal disability.   

In his current roles of Chief Executive Officer of the Oxford Academic Health Science Network, consultant physician at the Oxford University Hospitals NHS Foundation Trust, and visiting professor of Clinical Pharmacology at Oxford University, Prof Ford continues to spearhead clinical research.

Making a difference

Prof Ford has been instrumental in embedding research into almost every stroke unit in the UK, which at long last disproves William Olser’s edict, with not only medicine and electricity, but also other interventions, not imaginable in Osler’s days, contributing to better outcomes. His services to stroke service delivery and stroke research have been recognised by the award of a CBE.  


The NIHR is highlighting seven research legends whose work has shaped the NHS, as part of its celebrations for the NHS’s 70th birthday and the NIHR’s I Am Research campaign.

Read about our other Research Legends:


The views and opinions expressed in this blog are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health and Social Care.